<article article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10735496</article-id><article-id pub-id-type="pmc">2363351</article-id><article-id pub-id-type="pii">6691053</article-id><article-id pub-id-type="doi">10.1054/bjoc.1999.1053</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Windbichler</surname><given-names>G H</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hausmaninger</surname><given-names>H</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Stummvoll</surname><given-names>W</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Graf</surname><given-names>A H</given-names></name><xref ref-type="aff" rid="aff2">4</xref></contrib><contrib contrib-type="author"><name><surname>Kainz</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lahodny</surname><given-names>J</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Denison</surname><given-names>U</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib><contrib contrib-type="author"><name><surname>Müller-Holzner</surname><given-names>E</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Marth</surname><given-names>C</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Obstetrics and Gynaecology, University Hospital, Anichstrasse 35, Innsbruck, A-6020, Austria</aff><aff id="aff2"><label>2</label>Departments of Medical Oncology, <label>4</label>Obstetrics and Gynaecology, General Hospital, Muellner-Hauptstrasse 48, Salzburg, A-5020, Austria</aff><aff id="aff3"><label>3</label>Department of Gynaecology, Hospital Barmherzige Schwestern, Seilerstaette 4, Linz, A-4020, Austria</aff><aff id="aff5"><label>5</label>Department of Gynaecology, University Hospital, Waehringer Guertel 18–20, Vienna, A-1090, Austria</aff><aff id="aff6"><label>6</label>Department of Gynaecology, General Hospital, Probst-Führerstrasse 4, St Poelten, A-3100, Austria</aff><aff id="aff7"><label>7</label>Department of Obstetrics and Gynaecology, Wilhelminenspital, Pavillon 28, Montleartstrasse 37, Vienna, A-1160, Austria</aff><pub-date pub-type="epub"><day>21</day><month>02</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>03</month><year>2000</year></pub-date><volume>82</volume><issue>6</issue><fpage>1138</fpage><lpage>1144</lpage><history><date date-type="received"><day>24</day><month>05</month><year>1999</year></date><date date-type="rev-recd"><day>13</day><month>09</month><year>1999</year></date><date date-type="accepted"><day>24</day><month>09</month><year>1999</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p><offsets xml_i="3826" xml_f="4208" txt_i="11" txt_f="393">Intraperitoneal treatment with interferon-γ (IFN-γ) has been shown to achieve surgically documented responses in the second-line therapy of ovarian cancer. To assess its efficacy in the first-line therapy, we conducted a randomized controlled trial with 148 patients who had undergone primary surgery for FIGO stage Ic–IIIc ovarian cancer. In the control arm women received 100 mg m</offsets><sup><offsets xml_i="4213" xml_f="4215" txt_i="393" txt_f="395">−2</offsets></sup><offsets xml_i="4221" xml_f="4243" txt_i="395" txt_f="417">cisplatin and 600 mg m</offsets><sup><offsets xml_i="4248" xml_f="4250" txt_i="417" txt_f="419">−2</offsets></sup><offsets xml_i="4256" xml_f="4575" txt_i="419" txt_f="738">cyclophosphamide, the experimental arm included the above regimen with IFN-γ 0.1 mg subcutaneously on days 1, 3, 5, 15, 17 and 19 of each 28-day cycle. Progression-free survival at 3 years was improved from 38% in controls to 51% in the treatment group corresponding to median times to progression of 17 and 48 months (</offsets><italic><offsets xml_i="4583" xml_f="4584" txt_i="738" txt_f="739">P</offsets></italic><offsets xml_i="4593" xml_f="5179" txt_i="739" txt_f="1325"> = 0.031, relative risk of progression 0.48, confidence interval 0.28–0.82). Three-year overall survival was 58% and 74% accordingly (n.s., median not yet reached). Complete clinical responses were observed in 68% with IFN-γ versus 56% in controls (n.s.). Toxicity was comparable in both groups except for a mild flu-like syndrome, experienced by most patients after administration of IFN-γ. Thus, with acceptable toxicity, the inclusion of IFN-γ in the first-line chemotherapy of ovarian cancer yielded a benefit in prolonging progression-free survival. © 2000 Cancer Research Campaign</offsets></p></abstract><kwd-group><kwd>randomized phase III trial</kwd><kwd>multicentre study</kwd><kwd>ovarian cancer</kwd><kwd>interferon-type II</kwd></kwd-group></article-meta></front></article>